{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:14:35Z","timestamp":1792685675349,"version":"4.5.0"},"reference-count":244,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.addr.2026.115921","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T16:19:44Z","timestamp":1782317984000},"page":"115921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Light-controlled CRISPR\u2013dCas9 epigenome editing: advanced drug-delivery strategies and oncology applications"],"prefix":"10.1016","volume":"236","author":[{"given":"Naiyereh Alipour","family":"Eskandani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danial","family":"Mirzaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzieh","family":"Ramezani Farani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afrooz","family":"Hatami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Hatami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Ghasemzaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Majid","family":"Ghoreishian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Kyu","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Suk","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.addr.2026.115921_bb0005","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1042\/EBC20190037","article-title":"The DNA methylation landscape in cancer","volume":"63","author":"Skvortsova","year":"2019","journal-title":"Essays Biochem."},{"issue":"7","key":"10.1016\/j.addr.2026.115921_bb0010","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nrc3486","article-title":"Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host","volume":"13","author":"Timp","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10555-025-10253-7","article-title":"Epigenetic drugs in cancer therapy","volume":"44","author":"Suraweera","year":"2025","journal-title":"Cancer Metastasis Rev."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0020","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13148-021-01069-7","article-title":"Advances in epigenetic therapeutics with focus on solid tumors","volume":"13","author":"Jin","year":"2021","journal-title":"Clin. Epigenetics"},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0025","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41420-024-01803-z","article-title":"Cancer epigenetics: from laboratory studies and clinical trials to precision medicine","volume":"10","author":"Yu","year":"2024","journal-title":"Cell Death Discov."},{"issue":"2","key":"10.1016\/j.addr.2026.115921_bb0030","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cell.2013.06.044","article-title":"CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes","volume":"154","author":"Gilbert","year":"2013","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.addr.2026.115921_bb0035","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41592-020-0966-x","article-title":"An efficient KRAB domain for CRISPRi applications in human cells","volume":"17","author":"Alerasool","year":"2020","journal-title":"Nat. Methods"},{"issue":"8","key":"10.1016\/j.addr.2026.115921_bb0040","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41587-024-02320-1","article-title":"Epigenome editing technologies for discovery and medicine","volume":"42","author":"McCutcheon","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2026.115921_bb0045","doi-asserted-by":"crossref","unstructured":"Huang, H.-C., Wu, L.-F., Liu, K., & Ma, B.-G. Opto-CRISPR: new prospects for gene editing and regulation. Trends Biotechnol. Doi: https:\/\/doi.org\/10.1016\/j.tibtech.2025.06.018.","DOI":"10.1016\/j.tibtech.2025.06.018"},{"issue":"7463","key":"10.1016\/j.addr.2026.115921_bb0050","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nature12466","article-title":"Optical control of mammalian endogenous transcription and epigenetic states","volume":"500","author":"Konermann","year":"2013","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.addr.2026.115921_bb0055","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nchembio.1753","article-title":"A light-inducible CRISPR-Cas9 system for control of endogenous gene activation","volume":"11","author":"Polstein","year":"2015","journal-title":"Nat. Chem. Biol."},{"issue":"7","key":"10.1016\/j.addr.2026.115921_bb0060","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nbt.3245","article-title":"Photoactivatable CRISPR-Cas9 for optogenetic genome editing","volume":"33","author":"Nihongaki","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"45","key":"10.1016\/j.addr.2026.115921_bb0065","doi-asserted-by":"crossref","first-page":"11962","DOI":"10.1073\/pnas.1707190114","article-title":"Efficient synthesis of phycocyanobilin in mammalian cells for optogenetic control of cell signaling","volume":"114","author":"Uda","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"12","key":"10.1016\/j.addr.2026.115921_bb0070","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","article-title":"Base editing: precision chemistry on the genome and transcriptome of living cells","volume":"19","author":"Rees","year":"2018","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0075","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41556-020-00620-7","article-title":"CRISPR technologies for precise epigenome editing","volume":"23","author":"Nakamura","year":"2021","journal-title":"Nat. Cell Biol."},{"issue":"7467","key":"10.1016\/j.addr.2026.115921_bb0080","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature12627","article-title":"Tumour heterogeneity in the clinic","volume":"501","author":"Bedard","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0085","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-019-0174-y","article-title":"Epigenetic heterogeneity in cancer","volume":"7","author":"Guo","year":"2019","journal-title":"Biomark. Res."},{"issue":"9","key":"10.1016\/j.addr.2026.115921_bb0090","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.ymthe.2020.07.021","article-title":"Current status and challenges of DNA Base editing tools","volume":"28","author":"Jeong","year":"2020","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0095","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41392-021-00645-w","article-title":"Spatiotemporal control of CRISPR\/Cas9 gene editing","volume":"6","author":"Zhuo","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0100","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41392-024-02039-0","article-title":"Epigenetics-targeted drugs: current paradigms and future challenges","volume":"9","author":"Dai","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0105","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41420-024-01803-z","article-title":"Cancer epigenetics: from laboratory studies and clinical trials to precision medicine","volume":"10","author":"Yu","year":"2024","journal-title":"Cell Death Discov."},{"issue":"12","key":"10.1016\/j.addr.2026.115921_bb0110","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/nmeth.3630","article-title":"Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements","volume":"12","author":"Thakore","year":"2015","journal-title":"Nat. Methods"},{"issue":"6","key":"10.1016\/j.addr.2026.115921_bb0115","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41588-024-01706-w","article-title":"Systematic epigenome editing captures the context-dependent instructive function of chromatin modifications","volume":"56","author":"Policarpi","year":"2024","journal-title":"Nat. Genet."},{"issue":"9","key":"10.1016\/j.addr.2026.115921_bb0120","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/j.cell.2021.03.025","article-title":"Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing","volume":"184","author":"Nu\u00f1ez","year":"2021","journal-title":"Cell"},{"issue":"8003","key":"10.1016\/j.addr.2026.115921_bb0125","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/s41586-024-07087-8","article-title":"Durable and efficient gene silencing in vivo by hit-and-run epigenome editing","volume":"627","author":"Cappelluti","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115921_bb0130","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2022.01.013","article-title":"Delivery of CRISPR-Cas tools for in vivo genome editing therapy: trends and challenges","volume":"342","author":"Taha","year":"2022","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.addr.2026.115921_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10474","article-title":"Optimization of CRISPR-Cas system for clinical cancer therapy","volume":"8","author":"Meng","year":"2023","journal-title":"Bioeng. Transl. Med."},{"issue":"9","key":"10.1016\/j.addr.2026.115921_bb0140","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/s41587-024-02437-3","article-title":"Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR\u2013Cas9 ribonucleoprotein","volume":"43","author":"Chen","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2026.115921_bb0145","doi-asserted-by":"crossref","unstructured":"Asmamaw Mengstie, M. (2022). Viral vectors for the in vivo delivery of CRISPR components: advances and challenges [mini review]. Front. Bioeng. Biotechnol., Volume 10\u20132022. Doi: https:\/\/doi.org\/10.3389\/fbioe.2022.895713.","DOI":"10.3389\/fbioe.2022.895713"},{"issue":"7","key":"10.1016\/j.addr.2026.115921_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/v13071288","article-title":"Lentiviral vectors for delivery of gene-editing systems based on CRISPR\/Cas: current state and perspectives","volume":"13","author":"Dong","year":"2021","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0155","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s12951-022-01570-y","article-title":"Stimuli-responsive nanoformulations for CRISPR-Cas9 genome editing","volume":"20","author":"Fang","year":"2022","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.addr.2026.115921_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113891","article-title":"Nanotechnology-based delivery of CRISPR\/Cas9 for cancer treatment","volume":"176","author":"Xu","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.addr.2026.115921_bb0165","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.tibtech.2017.11.006","article-title":"Engineering the delivery system for CRISPR-based genome editing","volume":"36","author":"Glass","year":"2018","journal-title":"Trends Biotechnol."},{"issue":"3","key":"10.1016\/j.addr.2026.115921_bb0170","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkae1237","article-title":"A modular toolbox for the optogenetic deactivation of transcription","volume":"53","author":"Muench","year":"2025","journal-title":"Nucleic Acids Res."},{"issue":"17","key":"10.1016\/j.addr.2026.115921_bb0175","doi-asserted-by":"crossref","first-page":"9901","DOI":"10.1093\/nar\/gkx578","article-title":"dCas9-based epigenome editing suggests acquisition of histone methylation is not sufficient for target gene repression","volume":"45","author":"O\u2019Geen","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.addr.2026.115921_bb0180","unstructured":"Food, & Drug, A. (2023). FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease. FDA. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease."},{"issue":"8","key":"10.1016\/j.addr.2026.115921_bb0185","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41592-021-01207-2","article-title":"Transgenic mice for in vivo epigenome editing with CRISPR-based systems","volume":"18","author":"Gemberling","year":"2021","journal-title":"Nat. Methods"},{"issue":"6","key":"10.1016\/j.addr.2026.115921_bb0190","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf213","article-title":"Light-induced expression of gRNA allows for optogenetic gene editing of T lymphocytes in vivo","volume":"53","author":"Pulgarin","year":"2025","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1016\/j.addr.2026.115921_bb0195","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41568-022-00441-w","article-title":"CRISPR in cancer biology and therapy","volume":"22","author":"Katti","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2026.115921_bb0200","doi-asserted-by":"crossref","unstructured":"Horlbeck, M. A., Gilbert, L. A., Villalta, J. E., Adamson, B., Pak, R. A., Chen, Y., Fields, A. P., Park, C. Y., Corn, J. E., Kampmann, M., & Weissman, J. S. (2016). Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation. eLife, 5, e19760. Doi: https:\/\/doi.org\/10.7554\/eLife.19760.","DOI":"10.7554\/eLife.19760"},{"issue":"12","key":"10.1016\/j.addr.2026.115921_bb0205","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/nmeth.3630","article-title":"Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements","volume":"12","author":"Thakore","year":"2015","journal-title":"Nat. Methods"},{"issue":"3","key":"10.1016\/j.addr.2026.115921_bb0210","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cell.2014.09.039","article-title":"A protein-tagging system for signal amplification in gene expression and fluorescence imaging","volume":"159","author":"Tanenbaum","year":"2014","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.addr.2026.115921_bb0215","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nbt.3199","article-title":"Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers","volume":"33","author":"Hilton","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.addr.2026.115921_bb0220","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/nar\/gkw1112","article-title":"Efficient targeted DNA methylation with chimeric dCas9\u2013Dnmt3a\u2013Dnmt3L methyltransferase","volume":"45","author":"Stepper","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0225","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1073\/pnas.1417910112","article-title":"Engineering an improved light-induced dimer (iLID) for controlling the localization and activity of signaling proteins","volume":"112","author":"Guntas","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7","key":"10.1016\/j.addr.2026.115921_bb0230","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nmeth.3864","article-title":"A bacterial phytochrome-based optogenetic system controllable with near-infrared light","volume":"13","author":"Kaberniuk","year":"2016","journal-title":"Nat. Methods"},{"issue":"7266","key":"10.1016\/j.addr.2026.115921_bb0235","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/nature08446","article-title":"Spatiotemporal control of cell signalling using a light-switchable protein interaction","volume":"461","author":"Levskaya","year":"2009","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.addr.2026.115921_bb0240","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1515\/hsz-2014-0199","article-title":"Optogenetics for gene expression in mammalian cells","volume":"396","author":"M\u00fcller","year":"2015","journal-title":"Biol. Chem."},{"issue":"10","key":"10.1016\/j.addr.2026.115921_bb0245","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/nmeth.4430","article-title":"CRISPR\u2013Cas9-based photoactivatable transcription systems to induce neuronal differentiation","volume":"14","author":"Nihongaki","year":"2017","journal-title":"Nat. Methods"},{"issue":"11","key":"10.1016\/j.addr.2026.115921_bb0250","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s41592-018-0178-9","article-title":"Engineered anti-CRISPR proteins for optogenetic control of CRISPR\u2013Cas9","volume":"15","author":"Bubeck","year":"2018","journal-title":"Nat. Methods"},{"issue":"12","key":"10.1016\/j.addr.2026.115921_bb0255","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1093\/plcell\/koae255","article-title":"Seeing red: light- and temperature-dependent complex formation reveal new insights into phytochrome activity","volume":"36","author":"Osborne","year":"2024","journal-title":"Plant Cell"},{"issue":"5","key":"10.1016\/j.addr.2026.115921_bb0260","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/nprot.2018.022","article-title":"Near-infrared light\u2013controlled systems for gene transcription regulation, protein targeting and spectral multiplexing","volume":"13","author":"Redchuk","year":"2018","journal-title":"Nat. Protoc."},{"issue":"12","key":"10.1016\/j.addr.2026.115921_bb0265","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3390\/life10120318","article-title":"Bioluminescence-driven optogenetics","volume":"10","author":"Sureda-Vives","year":"2020","journal-title":"Life"},{"key":"10.1016\/j.addr.2026.115921_bb0270","doi-asserted-by":"crossref","unstructured":"Pan, Y., Yang, J., Luan, X., Liu, X., Li, X., Yang, J., Huang, T., Sun, L., Wang, Y., Lin, Y., & Song, Y. Near-infrared upconversion\u2013activated CRISPR-Cas9 system: a remote-controlled gene editing platform. Sci. Adv., 5(4), eaav7199. Doi: https:\/\/doi.org\/10.1126\/sciadv.aav7199.","DOI":"10.1126\/sciadv.aav7199"},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0275","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41377-025-01917-8","article-title":"Near-infrared light activatable chemically induced CRISPR system","volume":"14","author":"Zhang","year":"2025","journal-title":"Light Sci. Appl."},{"issue":"5","key":"10.1016\/j.addr.2026.115921_bb0280","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1093\/nar\/gkaa1198","article-title":"Optogenetic control of Neisseria meningitidis Cas9 genome editing using an engineered, light-switchable anti-CRISPR protein","volume":"49","author":"Hoffmann","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.addr.2026.115921_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2021.08.035","article-title":"Applications of upconversion nanoparticles in cellular optogenetics","volume":"135","author":"Lin","year":"2021","journal-title":"Acta Biomater."},{"issue":"10","key":"10.1016\/j.addr.2026.115921_bb0290","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/nbt.3658","article-title":"Targeted DNA demethylation in vivo using dCas9\u2013peptide repeat and scFv\u2013TET1 catalytic domain fusions","volume":"34","author":"Morita","year":"2016","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.addr.2026.115921_bb0295","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1093\/nar\/gkac123","article-title":"Determinants of heritable gene silencing for KRAB-dCas9 + DNMT3 and Ezh2-dCas9 + DNMT3 hit-and-run epigenome editing","volume":"50","author":"O\u2019Geen","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"19","key":"10.1016\/j.addr.2026.115921_bb0300","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914865","article-title":"CRISPR\/dCas9 tools: epigenetic mechanism and application in gene transcriptional regulation","volume":"24","author":"Cai","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.addr.2026.115921_bb0305","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.cell.2014.09.029","article-title":"Genome-scale CRISPR-mediated control of gene repression and activation","volume":"159","author":"Gilbert","year":"2014","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0310","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13059-025-03640-4","article-title":"Engineering novel CRISPRi repressors for highly efficient mammalian gene regulation","volume":"26","author":"Kristof","year":"2025","journal-title":"Genome Biol."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0315","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41467-020-14362-5","article-title":"Interrogation of enhancer function by enhancer-targeting CRISPR epigenetic editing","volume":"11","author":"Li","year":"2020","journal-title":"Nat. Commun."},{"issue":"7536","key":"10.1016\/j.addr.2026.115921_bb0320","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nature14136","article-title":"Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex","volume":"517","author":"Konermann","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0325","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/nar\/gkad1108","article-title":"A modular dCas9-based recruitment platform for combinatorial epigenome editing","volume":"52","author":"Swain","year":"2024","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.addr.2026.115921_bb0330","doi-asserted-by":"crossref","first-page":"R37","DOI":"10.1088\/0031-9155\/58\/11\/R37","article-title":"Optical properties of biological tissues: a review","volume":"58","author":"Jacques","year":"2013","journal-title":"Phys. Med. Biol."},{"key":"10.1016\/j.addr.2026.115921_bb0335","doi-asserted-by":"crossref","DOI":"10.1142\/S1793545811001319","article-title":"Optical properties of skin, subcutaneous, and muscle tissues: a review","volume":"4","author":"Bashkatov","year":"2011","journal-title":"J. Innov. Opt. Health Sci."},{"issue":"21","key":"10.1016\/j.addr.2026.115921_bb0340","doi-asserted-by":"crossref","first-page":"10659","DOI":"10.1021\/acs.chemrev.8b00163","article-title":"Blue-light receptors for optogenetics","volume":"118","author":"Losi","year":"2018","journal-title":"Chem. Rev."},{"issue":"11","key":"10.1016\/j.addr.2026.115921_bb0345","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1002\/bit.27895","article-title":"Clinical applicability of optogenetic gene regulation","volume":"118","author":"Wichert","year":"2021","journal-title":"Biotechnol. Bioeng."},{"issue":"4","key":"10.1016\/j.addr.2026.115921_bb0350","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41551-021-00829-3","article-title":"Towards translational optogenetics","volume":"7","author":"Bansal","year":"2023","journal-title":"Nat Biomed. Eng."},{"issue":"6","key":"10.1016\/j.addr.2026.115921_bb0355","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nchembio.2343","article-title":"Near-infrared optogenetic pair for protein regulation and spectral multiplexing","volume":"13","author":"Redchuk","year":"2017","journal-title":"Nat. Chem. Biol."},{"issue":"6376","key":"10.1016\/j.addr.2026.115921_bb0360","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1126\/science.aaq1144","article-title":"Near-infrared deep brain stimulation via upconversion nanoparticle-mediated optogenetics","volume":"359","author":"Chen","year":"2018","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.addr.2026.115921_bb0365","doi-asserted-by":"crossref","DOI":"10.1002\/bies.201700003","article-title":"Phototoxicity in live fluorescence microscopy, and how to avoid it","volume":"39","author":"Icha","year":"2017","journal-title":"Bioessays"},{"issue":"6","key":"10.1016\/j.addr.2026.115921_bb0370","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/s41587-023-01893-7","article-title":"Near-infrared co-illumination of fluorescent proteins reduces photobleaching and phototoxicity","volume":"42","author":"Ludvikova","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2026.115921_bb0375","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.19760","article-title":"Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation","volume":"5","author":"Horlbeck","year":"2016","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0380","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13072-019-0275-8","article-title":"Ezh2-dCas9 and KRAB-dCas9 enable engineering of epigenetic memory in a context-dependent manner","volume":"12","author":"O\u2019Geen","year":"2019","journal-title":"Epigenetics Chromatin"},{"issue":"18","key":"10.1016\/j.addr.2026.115921_bb0385","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkw583","article-title":"Optimizing sgRNA position markedly improves the efficiency of CRISPR\/dCas9-mediated transcriptional repression","volume":"44","author":"Radzisheuskaya","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.addr.2026.115921_bb0390","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.81856","article-title":"Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors","volume":"11","author":"Replogle","year":"2022","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0395","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/nar\/gkad1108","article-title":"A modular dCas9-based recruitment platform for combinatorial epigenome editing","volume":"52","author":"Swain","year":"2024","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.addr.2026.115921_bb0400","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/s41573-023-00762-x","article-title":"Drug delivery systems for CRISPR-based genome editors","volume":"22","author":"Madigan","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.addr.2026.115921_bb0405","doi-asserted-by":"crossref","DOI":"10.1063\/5.0228874","article-title":"In vivo delivery systems for CRISPR genome editing: viral and non-viral carriers","volume":"12","author":"Lee","year":"2025","journal-title":"Appl. Phys. Rev."},{"issue":"9","key":"10.1016\/j.addr.2026.115921_bb0410","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26094420","article-title":"CRISPR\/Cas9 delivery systems to enhance gene editing efficiency","volume":"26","author":"Seijas","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2026.115921_bb0415","series-title":"Epigenome Editing: Methods and Protocols","first-page":"267","article-title":"Protocol for delivery of CRISPR\/dCas9 Systems for Epigenetic Editing into solid Tumors using lipid nanoparticles encapsulating RNA","author":"Woodward","year":"2024"},{"issue":"10","key":"10.1016\/j.addr.2026.115921_bb0420","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201805730","article-title":"Degradability and clearance of inorganic nanoparticles for biomedical applications","volume":"31","author":"Yang","year":"2019","journal-title":"Adv. Mater."},{"issue":"6","key":"10.1016\/j.addr.2026.115921_bb0425","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13060770","article-title":"Degradation of Drug delivery nanocarriers and payload release: A review of physical methods for tracing nanocarrier biological fate","volume":"13","author":"Perrigue","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115921_bb0430","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.biomaterials.2018.04.031","article-title":"Non-viral delivery systems for CRISPR\/Cas9-based genome editing: challenges and opportunities","volume":"171","author":"Li","year":"2018","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.addr.2026.115921_bb0435","doi-asserted-by":"crossref","DOI":"10.1063\/5.0228874","article-title":"In vivo delivery systems for CRISPR genome editing: viral and non-viral carriers","volume":"12","author":"Lee","year":"2025","journal-title":"Appl. Phys. Rev."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0440","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cell.2020.03.023","article-title":"CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.addr.2026.115921_bb0445","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41417-023-00597-z","article-title":"Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR\/Cas-mediated cancer therapy","volume":"30","author":"Ahmadi","year":"2023","journal-title":"Cancer Gene Ther."},{"issue":"2","key":"10.1016\/j.addr.2026.115921_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e24606","article-title":"Lipid nanoparticles: the game-changer in CRISPR-Cas9 genome editing","volume":"10","author":"Mohammadian Farsani","year":"2024","journal-title":"Heliyon"},{"issue":"10","key":"10.1016\/j.addr.2026.115921_bb0455","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020401118","article-title":"Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of <i>Angptl3<\/i>","volume":"118","author":"Qiu","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"10.1016\/j.addr.2026.115921_bb0460","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3390\/pharmaceutics16091197","article-title":"Advances in nanoparticles as non-viral vectors for efficient delivery of CRISPR\/Cas9","volume":"16","author":"Kim","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115921_bb0465","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2023.1259435","article-title":"Biomaterials-mediated CRISPR\/Cas9 delivery: recent challenges and opportunities in gene therapy","volume":"11","author":"Dubey","year":"2023","journal-title":"Front. Chem."},{"issue":"3","key":"10.1016\/j.addr.2026.115921_bb0470","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3390\/molecules30030542","article-title":"CRISPR-Cas9 gene therapy: non-viral delivery and stimuli-responsive Nanoformulations","volume":"30","author":"Lee","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2026.115921_bb0475","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.942325","article-title":"CRISPR\/Cas systems: delivery and application in gene therapy","volume":"10","author":"Huang","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.addr.2026.115921_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119711","article-title":"Ex vivo cell-based CRISPR\/Cas9 genome editing for therapeutic applications","volume":"234","author":"Li","year":"2020","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0485","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s12951-022-01570-y","article-title":"Stimuli-responsive nanoformulations for CRISPR-Cas9 genome editing","volume":"20","author":"Fang","year":"2022","journal-title":"J. Nanobiotechnol."},{"issue":"23","key":"10.1016\/j.addr.2026.115921_bb0490","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202110618","article-title":"pH-responsive polymer nanoparticles for efficient delivery of Cas9 ribonucleoprotein with or without donor DNA","volume":"34","author":"Xie","year":"2022","journal-title":"Adv. Mater."},{"issue":"10","key":"10.1016\/j.addr.2026.115921_bb0495","doi-asserted-by":"crossref","first-page":"8904","DOI":"10.1007\/s12274-024-6748-5","article-title":"Viral and nonviral nanocarriers for in vivo CRISPR-based gene editing","volume":"17","author":"Guo","year":"2024","journal-title":"Nano Res."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0500","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/s12951-025-03523-7","article-title":"Transdermal delivery of CRISPR\/Cas9-mediated melanoma gene therapy via polyamines-modified thermosensitive hydrogels","volume":"23","author":"Li","year":"2025","journal-title":"J. Nanobiotechnol."},{"issue":"9","key":"10.1016\/j.addr.2026.115921_bb0505","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1039\/D4MA00122B","article-title":"Hydrogels as local depots for on-demand therapeutic delivery: potential therapeutic approaches for tumor metastasis","volume":"5","author":"Andrgie","year":"2024","journal-title":"Materials Advances"},{"key":"10.1016\/j.addr.2026.115921_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2024.148733","article-title":"Delivery of CRISPR\/Cas9 system by AAV as vectors for gene therapy","volume":"927","author":"Wang","year":"2024","journal-title":"Gene"},{"key":"10.1016\/j.addr.2026.115921_bb0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123314","article-title":"Engineering adeno-associated viral vectors for CRISPR\/Cas based in vivo therapeutic genome editing","volume":"321","author":"Moyo","year":"2025","journal-title":"Biomaterials"},{"issue":"12","key":"10.1016\/j.addr.2026.115921_bb0520","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1007\/s11427-023-2608-5","article-title":"AAV-mediated gene therapies by miniature gene editing tools","volume":"67","author":"Kong","year":"2024","journal-title":"Sci. China Life Sci."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0525","doi-asserted-by":"crossref","first-page":"7259","DOI":"10.1038\/s41467-024-50515-6","article-title":"The therapeutic implications of all-in-one AAV-delivered epigenome-editing platform in neurodegenerative disorders","volume":"15","author":"Kantor","year":"2024","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.addr.2026.115921_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102395","article-title":"Cell-specific delivery of CRISPR-Cas9 with pseudotyped lentiviral particles: just change the envelope","volume":"35","author":"Covo-Vergara","year":"2024","journal-title":"Molecular Therapy - Nucleic Acids"},{"issue":"6","key":"10.1016\/j.addr.2026.115921_bb0535","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore Julian","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115921_bb0540","article-title":"Programmable lipid nanoparticles for RNA therapeutics: design principles and clinical translation","volume":"37","author":"Navid Talemi","year":"2026","journal-title":"Mater Today Bio"},{"issue":"6","key":"10.1016\/j.addr.2026.115921_bb0545","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","article-title":"Lipid-nanoparticle-based delivery of CRISPR\/Cas9 genome-editing components","volume":"19","author":"Kazemian","year":"2022","journal-title":"Mol. Pharm."},{"issue":"10","key":"10.1016\/j.addr.2026.115921_bb0550","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020401118","article-title":"Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3","volume":"118","author":"Qiu","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2026.115921_bb0555","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-1-0716-4051-7_14","article-title":"Protocol for delivery of CRISPR\/dCas9 Systems for Epigenetic Editing into solid Tumors using lipid nanoparticles encapsulating RNA","volume":"2842","author":"Woodward","year":"2024","journal-title":"Methods Mol. Biol."},{"issue":"22","key":"10.1016\/j.addr.2026.115921_bb0560","article-title":"Synthetic epigenetic reprogramming of mesenchymal to epithelial states using the CRISPR\/dCas9 platform in triple negative breast Cancer","volume":"10","author":"Waryah","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.addr.2026.115921_bb0565","doi-asserted-by":"crossref","unstructured":"Huang, J., Zhou, Y., Li, J., Lu, A., & Liang, C. (2022). CRISPR\/Cas systems: delivery and application in gene therapy [review]. Front. Bioeng. Biotechnol., Volume 10\u20132022. Doi: https:\/\/doi.org\/10.3389\/fbioe.2022.942325.","DOI":"10.3389\/fbioe.2022.942325"},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0570","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s40820-023-01018-4","article-title":"Stimuli-responsive gene delivery nanocarriers for Cancer therapy","volume":"15","author":"Zhang","year":"2023","journal-title":"Nano-Micro Lett."},{"key":"10.1016\/j.addr.2026.115921_bb0575","doi-asserted-by":"crossref","unstructured":"Duan, L., Ouyang, K., Xu, X., Xu, L., Wen, C., Zhou, X., Qin, Z., Xu, Z., Sun, W., & Liang, Y. (2021). Nanoparticle delivery of CRISPR\/Cas9 for genome editing [review]. Front. Genet., Volume 12\u20132021. Doi: https:\/\/doi.org\/10.3389\/fgene.2021.673286.","DOI":"10.3389\/fgene.2021.673286"},{"key":"10.1016\/j.addr.2026.115921_bb0580","doi-asserted-by":"crossref","unstructured":"Xie, R., Wang, Y., & Gong, S. (2021). External stimuli-responsive nanoparticles for spatially and temporally controlled delivery of CRISPR\u2013Cas genome editors [10.1039\/D1BM00558H]. Biomater. Sci., 9(18), 6012\u20136022. Doi: https:\/\/doi.org\/10.1039\/D1BM00558H.","DOI":"10.1039\/D1BM00558H"},{"issue":"17","key":"10.1016\/j.addr.2026.115921_bb0585","doi-asserted-by":"crossref","first-page":"7783","DOI":"10.1021\/jacs.9b13813","article-title":"Biodegradable gold nanoclusters with improved excretion due to pH-triggered hydrophobic-to-hydrophilic transition","volume":"142","author":"Higbee-Dempsey","year":"2020","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0590","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1038\/s41467-019-12142-4","article-title":"Near-infrared light and tumor microenvironment dual responsive size-switchable nanocapsules for multimodal tumor theranostics","volume":"10","author":"Wang","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0595","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41413-022-00212-1","article-title":"Prospects and challenges of dynamic DNA nanostructures in biomedical applications","volume":"10","author":"Tian","year":"2022","journal-title":"Bone Res"},{"issue":"6","key":"10.1016\/j.addr.2026.115921_bb0600","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1021\/ar500073a","article-title":"DNA nanotechnology based on i-motif structures","volume":"47","author":"Dong","year":"2014","journal-title":"Acc. Chem. Res."},{"issue":"4","key":"10.1016\/j.addr.2026.115921_bb0605","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1021\/acs.molpharmaceut.9b01159","article-title":"Facile construction of i-motif DNA-conjugated gold Nanostars as near-infrared and pH dual-responsive targeted Drug delivery Systems for Combined Cancer Therapy","volume":"17","author":"Miao","year":"2020","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.addr.2026.115921_bb0610","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40005-024-00678-7","article-title":"Injectable hydrogel systems for local cancer therapy","volume":"54","author":"Kim","year":"2024","journal-title":"J. Pharm. Investig."},{"issue":"7","key":"10.1016\/j.addr.2026.115921_bb0615","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3390\/nano15070540","article-title":"Precisely targeted nanoparticles for CRISPR-Cas9 delivery in clinical applications","volume":"15","author":"Liu","year":"2025","journal-title":"Nanomaterials"},{"issue":"15","key":"10.1016\/j.addr.2026.115921_bb0620","doi-asserted-by":"crossref","DOI":"10.3390\/cells14151136","article-title":"Nanotechnology-based delivery of CRISPR\/Cas9 for cancer treatment: a comprehensive review","volume":"14","author":"Rauf","year":"2025","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.addr.2026.115921_bb0625","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.tig.2022.05.014","article-title":"Optogenetics for transcriptional programming and genetic engineering","volume":"38","author":"Lan","year":"2022","journal-title":"Trends Genet."},{"issue":"11","key":"10.1016\/j.addr.2026.115921_bb0630","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nrc.2016.82","article-title":"Metabolic control of epigenetics in cancer","volume":"16","author":"Kinnaird","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.addr.2026.115921_bb0635","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s12276-023-01020-1","article-title":"Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential","volume":"55","author":"Xu","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"6632","key":"10.1016\/j.addr.2026.115921_bb0640","doi-asserted-by":"crossref","first-page":"eaaw3835","DOI":"10.1126\/science.aaw3835","article-title":"Epigenetics as a mediator of plasticity in cancer","volume":"379","author":"Feinberg","year":"2023","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.addr.2026.115921_bb0645","doi-asserted-by":"crossref","DOI":"10.3390\/cells11091403","article-title":"Targeting epigenetic modifiers of tumor plasticity and Cancer stem cell behavior","volume":"11","author":"Kumar","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0650","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/s41467-019-10146-8","article-title":"Targeted removal of epigenetic barriers during transcriptional reprogramming","volume":"10","author":"Baumann","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0655","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-023-01480-x","article-title":"Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0660","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1038\/s41467-019-12166-w","article-title":"Epigenome editing strategies for the functional annotation of CTCF insulators","volume":"10","author":"Tarjan","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115921_bb0665","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-025-02856-w","article-title":"Integrated epigenetic and genetic programming of primary human T cells","author":"Goudy","year":"2025","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0670","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.cell.2016.08.056","article-title":"Editing DNA methylation in the mammalian genome","volume":"167","author":"Liu","year":"2016","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0675","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13148-023-01482-0","article-title":"Epigenetic reactivation of tumor suppressor genes with CRISPRa technologies as precision therapy for hepatocellular carcinoma","volume":"15","author":"Sgro","year":"2023","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.addr.2026.115921_bb0680","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.omtn.2018.12.003","article-title":"Activating PTEN tumor suppressor expression with the CRISPR\/dCas9 system","volume":"14","author":"Moses","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"issue":"5","key":"10.1016\/j.addr.2026.115921_bb0685","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.1016\/j.jid.2023.03.864","article-title":"854 CRISPR-Cas9-based epigenome editing targeting the CDKN2A promoter reactivates the p16<sup>INK4A<\/sup> tumor suppressor and inhibits proliferation of skin cancer cells","volume":"143","author":"Eng","year":"2023","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.addr.2026.115921_bb0690","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.molcel.2016.03.007","article-title":"Enhancer regulation of transcriptional bursting parameters revealed by forced chromatin looping","volume":"62","author":"Bartman","year":"2016","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0695","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.addr.2026.115921_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101821","article-title":"Epigenetic modifications: key players in cancer heterogeneity and drug resistance","volume":"39","author":"Sadida","year":"2024","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.addr.2026.115921_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2023.100929","article-title":"Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma","volume":"44","author":"Han","year":"2023","journal-title":"Neoplasia"},{"issue":"2","key":"10.1016\/j.addr.2026.115921_bb0710","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.celrep.2018.03.056","article-title":"Transcriptional dysregulation of MYC reveals common enhancer-docking mechanism","volume":"23","author":"Schuijers","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.addr.2026.115921_bb0715","article-title":"Reshaping tumor immune microenvironment through ROS-responsive prodrug polyplexes via synergistic effect of CRISPRi system and epigenetic inhibitor for breast cancer therapy","volume":"35","author":"Deng","year":"2025","journal-title":"Mater. Today Bio"},{"issue":"6487","key":"10.1016\/j.addr.2026.115921_bb0720","doi-asserted-by":"crossref","first-page":"eaaw5473","DOI":"10.1126\/science.aaw5473","article-title":"Metabolic reprogramming and cancer progression","volume":"368","author":"Faubert","year":"2020","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.addr.2026.115921_bb0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111630","article-title":"Systematic discovery and functional dissection of enhancers needed for cancer cell fitness and proliferation","volume":"41","author":"Chen","year":"2022","journal-title":"Cell Rep."},{"issue":"7","key":"10.1016\/j.addr.2026.115921_bb0730","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s12276-023-01020-1","article-title":"Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential","volume":"55","author":"Xu","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"3","key":"10.1016\/j.addr.2026.115921_bb0735","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41568-022-00543-5","article-title":"Acetyl-CoA metabolism in cancer","volume":"23","author":"Guertin","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.addr.2026.115921_bb0740","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-19-0061","article-title":"Glioma stem cell\u2013specific superenhancer promotes polyunsaturated fatty-acid synthesis to support EGFR signaling","volume":"9","author":"Gimple","year":"2019","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0745","doi-asserted-by":"crossref","first-page":"7139","DOI":"10.1038\/s41467-021-27055-4","article-title":"A predominant enhancer co-amplified with the SOX2 oncogene is necessary and sufficient for its expression in squamous cancer","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.addr.2026.115921_bb0750","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.stem.2017.12.001","article-title":"CRISPR-based chromatin Remodeling of the endogenous Oct4 or Sox2 locus enables reprogramming to pluripotency","volume":"22","author":"Liu","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"6","key":"10.1016\/j.addr.2026.115921_bb0755","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2310821121","article-title":"Targeted demethylation and activation of NLRC5 augment cancer immunogenicity through MHC class I","volume":"121","author":"Sun","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.addr.2026.115921_bb0760","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/biof.1285","article-title":"CITA\/NLRC5: A critical transcriptional regulator of MHC class I gene expression","volume":"42","author":"Downs","year":"2016","journal-title":"Biofactors"},{"issue":"5","key":"10.1016\/j.addr.2026.115921_bb0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107205","article-title":"The balance between nuclear import and export of NLRC5 regulates MHC class I transactivation","volume":"300","author":"Zhu","year":"2024","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0770","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13072-017-0129-1","article-title":"Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells","volume":"10","author":"Okada","year":"2017","journal-title":"Epigenetics Chromatin"},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0775","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cell.2016.09.006","article-title":"Inheritable silencing of endogenous genes by hit-and-run targeted epigenetic editing","volume":"167","author":"Amabile","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.addr.2026.115921_bb0780","article-title":"A light-inducible Split-dCas9 system for inhibiting the progression of bladder Cancer cells by activating p53 and E-cadherin","volume":"7","author":"Huang","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.addr.2026.115921_bb0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2023.100929","article-title":"Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma","volume":"44","author":"Han","year":"2023","journal-title":"Neoplasia"},{"key":"10.1016\/j.addr.2026.115921_bb0790","doi-asserted-by":"crossref","unstructured":"Huang, X., Zhou, Q., Wang, M., Cao, C., Ma, Q., Ye, J., & Gui, Y. (2021). A light-inducible split-dCas9 system for inhibiting the progression of bladder cancer cells by activating p53 and E-cadherin [original research]. Front. Mol. Biosci., Volume 7\u20132020. Doi: https:\/\/doi.org\/10.3389\/fmolb.2020.627848.","DOI":"10.3389\/fmolb.2020.627848"},{"key":"10.1016\/j.addr.2026.115921_bb0795","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.omtn.2018.12.003","article-title":"Activating <em>PTEN<\/em> tumor suppressor expression with the CRISPR\/dCas9 system","volume":"14","author":"Moses","year":"2019","journal-title":"Molecular Therapy Nucleic Acids"},{"key":"10.1016\/j.addr.2026.115921_bb0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2022.124071","article-title":"A sensitive \u201cturn-on\u201d fluorescent biosensor for the detection of biomarkers based on three-dimensional DNA walker","volume":"253","author":"Xie","year":"2023","journal-title":"Talanta"},{"issue":"2","key":"10.1016\/j.addr.2026.115921_bb0805","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.celrep.2018.03.056","article-title":"Transcriptional dysregulation of <em>MYC<\/em> reveals common enhancer-docking mechanism","volume":"23","author":"Schuijers","year":"2018","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.addr.2026.115921_bb0810","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/gigascience\/giy011","article-title":"Genome-wide determination of on-target and off-target characteristics for RNA-guided DNA methylation by dCas9 methyltransferases","volume":"7","author":"Lin","year":"2018","journal-title":"Gigascience"},{"issue":"8","key":"10.1016\/j.addr.2026.115921_bb0815","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1101\/gr.233049.117","article-title":"A modular dCas9-SunTag DNMT3A epigenome editing system overcomes pervasive off-target activity of direct fusion dCas9-DNMT3A constructs","volume":"28","author":"Pflueger","year":"2018","journal-title":"Genome Res."},{"issue":"4","key":"10.1016\/j.addr.2026.115921_bb0820","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/s41591-025-03508-x","article-title":"A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels","volume":"31","author":"Tremblay","year":"2025","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.addr.2026.115921_bb0825","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41592-021-01207-2","article-title":"Transgenic mice for in vivo epigenome editing with CRISPR-based systems","volume":"18","author":"Gemberling","year":"2021","journal-title":"Nat. Methods"},{"issue":"11","key":"10.1016\/j.addr.2026.115921_bb0830","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.medj.2024.08.010","article-title":"Patient-derived organoids in precision cancer medicine","volume":"5","author":"Tong","year":"2024","journal-title":"Med"},{"issue":"3","key":"10.1016\/j.addr.2026.115921_bb0835","article-title":"Humanized mouse models for Immuno-oncology research: A review and implications in lung Cancer research","volume":"6","author":"Park","year":"2025","journal-title":"JTO Clin Res Rep"},{"issue":"11","key":"10.1016\/j.addr.2026.115921_bb0840","article-title":"Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges","volume":"5","author":"Li","year":"2024","journal-title":"MedComm (2020)"},{"issue":"49","key":"10.1016\/j.addr.2026.115921_bb0845","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1038\/s41388-025-03624-5","article-title":"From concept to clinic: a roadmap for DNA methylation biomarkers in liquid biopsies","volume":"44","author":"Pharo","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.addr.2026.115921_bb0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2022.108005","article-title":"Optogenetic technologies in translational cancer research","volume":"60","author":"Malogolovkin","year":"2022","journal-title":"Biotechnol. Adv."},{"issue":"13","key":"10.1016\/j.addr.2026.115921_bb0855","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16132484","article-title":"Devices and methods for dosimetry of personalized photodynamic therapy of tumors: a review on recent trends","volume":"16","author":"Alekseeva","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0860","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12967-022-03405-8","article-title":"Patient-derived xenograft (PDX) models, applications and challenges in cancer research","volume":"20","author":"Abdolahi","year":"2022","journal-title":"J. Transl. Med."},{"issue":"7","key":"10.1016\/j.addr.2026.115921_bb0865","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.stem.2023.05.012","article-title":"Organoid cultures for cancer modeling","volume":"30","author":"Yan","year":"2023","journal-title":"Cell Stem Cell"},{"issue":"3","key":"10.1016\/j.addr.2026.115921_bb0870","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","article-title":"Humanized mouse models for immuno-oncology research","volume":"20","author":"Chuprin","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.addr.2026.115921_bb0875","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/s41596-022-00692-9","article-title":"Chromatin accessibility profiling by ATAC-seq","volume":"17","author":"Grandi","year":"2022","journal-title":"Nat. Protoc."},{"issue":"9","key":"10.1016\/j.addr.2026.115921_bb0880","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.cels.2024.08.004","article-title":"Discovery of therapeutic targets in cancer using chromatin accessibility and transcriptomic data","volume":"15","author":"Forbes","year":"2024","journal-title":"Cell Syst."},{"issue":"3","key":"10.1016\/j.addr.2026.115921_bb0885","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s10555-020-09876-9","article-title":"Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy","volume":"39","author":"Boonstra","year":"2020","journal-title":"Cancer and Metastasis Reviews"},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0890","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"Bartolomucci","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.addr.2026.115921_bb0895","unstructured":"Research, C. f. B. E. a. (2020). Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs). U.S. Food and Drug Administration. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/chemistry-manufacturing-and-control-cmc-information-human-gene-therapy-investigational-new-drug."},{"key":"10.1016\/j.addr.2026.115921_bb0900","series-title":"S12 Nonclinical Biodistribution Considerations for Gene Therapy PRODUC","author":"Center","year":"2023"},{"key":"10.1016\/j.addr.2026.115921_bb0905","series-title":"Human Gene Therapy Products Incorporating Human Genome Editing","author":"Center for Biologics, E., & Research","year":"2022"},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0910","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13046-024-02993-1","article-title":"GMP-manufactured CRISPR\/Cas9 technology as an advantageous tool to support cancer immunotherapy","volume":"43","author":"Caforio","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.addr.2026.115921_bb0915","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jcyt.2024.11.015","article-title":"Considerations for manufacturing of cell and gene medicines for clinical development","volume":"27","author":"Lowdell","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.addr.2026.115921_bb0920","article-title":"Potency testing of cell and gene therapy products","volume":"10","author":"Salmikangas","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.addr.2026.115921_bb0925","doi-asserted-by":"crossref","DOI":"10.1007\/s43441-026-00920-4","article-title":"Outlook of cell gene therapies development and approval from quality and regulatory perspective","author":"Iglesias-Lopez","year":"2026","journal-title":"Ther. Innov. Regul. Sci."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0930","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10","key":"10.1016\/j.addr.2026.115921_bb0935","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1016\/j.ymthe.2025.06.045","article-title":"Peeling back the layers of immunogenicity in Cas9-based genomic medicine","volume":"33","author":"Stigzelius","year":"2025","journal-title":"Mol. Ther."},{"issue":"5\u20136","key":"10.1016\/j.addr.2026.115921_bb0940","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41434-023-00410-4","article-title":"Preclinical safety and biodistribution of CRISPR targeting SIV in non-human primates","volume":"31","author":"Burdo","year":"2024","journal-title":"Gene Ther."},{"issue":"8","key":"10.1016\/j.addr.2026.115921_bb0945","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/s41587-023-01974-7","article-title":"Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration","volume":"42","author":"Greig","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.addr.2026.115921_bb0950","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41434-025-00514-z","article-title":"Incomplete elimination of viral genomes is associated with chronic inflammation in nonhuman primate livers after AAV-mediated gene transfer","volume":"32","author":"Pichard","year":"2025","journal-title":"Gene Ther."},{"issue":"7","key":"10.1016\/j.addr.2026.115921_bb0955","doi-asserted-by":"crossref","DOI":"10.3390\/cells15070644","article-title":"CRISPR-Cas9 therapeutics in early clinical development: delivery and molecular diagnostics","volume":"15","author":"Rutkowska","year":"2026","journal-title":"Cells"},{"key":"10.1016\/j.addr.2026.115921_bb0960","unstructured":"FDA: Genome editing therapies may use accelerated approval pathway. (2024). Raps.org. https:\/\/www.raps.org\/news-and-articles\/news-articles\/2024\/1\/fda-genome-editing-therapies-may-use-accelerated-a."},{"key":"10.1016\/j.addr.2026.115921_bb0965","unstructured":"Research, C. f. B. E. a. (2019). Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products. U.S. Food and Drug Administration. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/design-and-analysis-shedding-studies-virus-or-bacteria-based-gene-therapy-and-oncolytic-products."},{"issue":"2","key":"10.1016\/j.addr.2026.115921_bb0970","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.addr.2026.115921_bb0975","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2023.01.010","article-title":"Binding and neutralizing anti-AAV antibodies: detection and implications for rAAV-mediated gene therapy","volume":"31","author":"Schulz","year":"2023","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0980","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41392-023-01309-7","article-title":"CRISPR\/Cas9 therapeutics: progress and prospects","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2026.115921_bb0985","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1138596","article-title":"Immunogenicity of CRISPR therapeutics-critical considerations for clinical translation","volume":"11","author":"Ewaisha","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb0990","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","article-title":"Delivering CRISPR: a review of the challenges and approaches","volume":"25","author":"Lino","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2026.115921_bb0995","first-page":"492","article-title":"Regulatory perspectives of combination products","volume":"10","author":"Tian","year":"2022","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.addr.2026.115921_bb1000","doi-asserted-by":"crossref","unstructured":"Cao, J., Zhu, B., Zheng, K., He, S., Meng, L., Song, J., & Yang, H. (2020). Recent progress in NIR-II contrast agent for biological imaging [review]. Front. Bioeng. Biotechnol., Volume 7\u20132019. Doi: https:\/\/doi.org\/10.3389\/fbioe.2019.00487.","DOI":"10.3389\/fbioe.2019.00487"},{"key":"10.1016\/j.addr.2026.115921_bb1005","doi-asserted-by":"crossref","unstructured":"Alghamdi, R. A., Exposito-Rodriguez, M., Mullineaux, P. M., Brooke, G. N., & Laissue, P. P. (2021). Assessing phototoxicity in a mammalian cell line: how low levels of blue light affect motility in PC3 cells [original research]. Front. Cell Dev. Biol., Volume 9\u20132021. Doi: https:\/\/doi.org\/10.3389\/fcell.2021.738786.","DOI":"10.3389\/fcell.2021.738786"},{"issue":"3","key":"10.1016\/j.addr.2026.115921_bb1010","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101273","article-title":"Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapies","volume":"32","author":"Chhabra","year":"2024","journal-title":"Molecular Therapy Methods & Clinical Development"},{"issue":"13","key":"10.1016\/j.addr.2026.115921_bb1015","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1093\/nar\/gkv601","article-title":"Development of an intein-mediated split\u2013Cas9 system for gene therapy","volume":"43","author":"Truong","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.addr.2026.115921_bb1020","unstructured":"Center for, D., & Radiological, H. (2019). Human Factors and Usability Engineering to Medical Devices. U.S. Food and Drug Administration. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/applying-human-factors-and-usability-engineering-medical-devices."},{"key":"10.1016\/j.addr.2026.115921_bb1025","series-title":"Shedding Studies for Virus, Bacteria-Based Gene Therapy","author":"Center.","year":"2019"},{"issue":"2","key":"10.1016\/j.addr.2026.115921_bb1030","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/php.13219","article-title":"Light sources and dosimetry techniques for photodynamic therapy","volume":"96","author":"Kim","year":"2020","journal-title":"Photochem. Photobiol."},{"issue":"6","key":"10.1016\/j.addr.2026.115921_bb1035","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nchembio.2343","article-title":"Near-infrared optogenetic pair for protein regulation and spectral multiplexing","volume":"13","author":"Redchuk","year":"2017","journal-title":"Nat. Chem. Biol."},{"issue":"5","key":"10.1016\/j.addr.2026.115921_bb1040","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7150\/thno.5284","article-title":"Upconversion nanoparticles for photodynamic therapy and other cancer therapeutics","volume":"3","author":"Wang","year":"2013","journal-title":"Theranostics"},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2026.115921_bb1045","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.6004\/jnccn.2012.0178","article-title":"Dosimetry in pleural photodynamic therapy","volume":"10","author":"Zhu","year":"2012","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb1050","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.neuron.2015.03.034","article-title":"Closed-loop and activity-guided optogenetic control","volume":"86","author":"Grosenick","year":"2015","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb1055","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13059-023-02930-z","article-title":"CasKAS: direct profiling of genome-wide dCas9 and Cas9 specificity using ssDNA mapping","volume":"24","author":"Marinov","year":"2023","journal-title":"Genome Biol."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb1060","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12864-021-08234-5","article-title":"Computational modeling of chromatin accessibility identified important epigenomic regulators","volume":"23","author":"Zhao","year":"2022","journal-title":"BMC Genomics"},{"issue":"10","key":"10.1016\/j.addr.2026.115921_bb1065","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/s41592-021-01252-x","article-title":"Effective gene expression prediction from sequence by integrating long-range interactions","volume":"18","author":"Avsec","year":"2021","journal-title":"Nat. Methods"},{"issue":"2","key":"10.1016\/j.addr.2026.115921_bb1070","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12864-019-5489-4","article-title":"DeepHistone: a deep learning approach to predicting histone modifications","volume":"20","author":"Yin","year":"2019","journal-title":"BMC Genomics"},{"key":"10.1016\/j.addr.2026.115921_bb1075","unstructured":"Office of the, C. (2019). Combination Product Definition Combination Product Types. FDA. https:\/\/www.fda.gov\/combination-products\/about-combination-products\/combination-product-definition-combination-product-types."},{"issue":"2","key":"10.1016\/j.addr.2026.115921_bb1080","doi-asserted-by":"crossref","DOI":"10.1007\/s12247-025-09973-8","article-title":"Cell and gene therapy products: navigating the regulatory landscape of paradigm approvals in the US (2020 to 2024)","volume":"20","author":"Tandulje","year":"2025","journal-title":"J. Pharm. Innov."},{"issue":"3","key":"10.1016\/j.addr.2026.115921_bb1085","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27031484","article-title":"From bench to bedside: ethical and clinical best practices for genome editing applications","volume":"27","author":"Ortiz-Bueno","year":"2026","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.addr.2026.115921_bb1090","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104337","article-title":"Long-term follow-up after authorization of gene therapy: leveraging real-world data","volume":"30","author":"de Haart","year":"2025","journal-title":"Drug Discov. Today"},{"issue":"10","key":"10.1016\/j.addr.2026.115921_bb1095","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.tibtech.2023.04.002","article-title":"Challenges in scaling up AAV-based gene therapy manufacturing","volume":"41","author":"Jiang","year":"2023","journal-title":"Trends Biotechnol."},{"issue":"8","key":"10.1016\/j.addr.2026.115921_bb1100","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jval.2023.03.009","article-title":"Frameworks for health technology assessment at an early stage of product development: A review and roadmap to guide applications","volume":"26","author":"Rodriguez Llorian","year":"2023","journal-title":"Value Health"},{"issue":"12","key":"10.1016\/j.addr.2026.115921_bb1105","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.healthpol.2019.07.009","article-title":"Challenges in the value assessment, pricing and funding of targeted combination therapies in oncology","volume":"123","author":"Dank\u00f3","year":"2019","journal-title":"Health Policy"},{"issue":"11","key":"10.1016\/j.addr.2026.115921_bb1110","doi-asserted-by":"crossref","DOI":"10.1093\/pnasnexus\/pgad394","article-title":"Readministration of high-dose adeno-associated virus gene therapy vectors enabled by ImmTOR nanoparticles combined with B cell-targeted agents","volume":"2","author":"Ilyinskii","year":"2023","journal-title":"PNAS Nexus"},{"key":"10.1016\/j.addr.2026.115921_bb1115","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jconrel.2021.05.021","article-title":"Impact of lipid nanoparticle size on mRNA vaccine immunogenicity","volume":"335","author":"Hassett","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115921_bb1120","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.trsl.2021.11.009","article-title":"Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials","volume":"242","author":"Whitley","year":"2022","journal-title":"Transl. Res."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb1125","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41568-024-00757-9","article-title":"Epigenomic heterogeneity as a source of tumour evolution","volume":"25","author":"Laisn\u00e9","year":"2025","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.addr.2026.115921_bb1130","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.37349\/etat.2024.00278","article-title":"Predictive and prognostic biomarkers in cancer: towards the precision medicine era","volume":"5","author":"Marletta","year":"2024","journal-title":"Explor Target Antitumor Ther"},{"issue":"8","key":"10.1016\/j.addr.2026.115921_bb1135","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15082075","article-title":"Advanced light source Technologies for Photodynamic Therapy of skin Cancer lesions","volume":"15","author":"Algorri","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb1140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41417-022-00495-w","article-title":"Application of ATAC-seq in tumor-specific T cell exhaustion","volume":"30","author":"Chen","year":"2023","journal-title":"Cancer Gene Ther."},{"issue":"11","key":"10.1016\/j.addr.2026.115921_bb1145","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/oncolo\/oyac134","article-title":"Implementation and clinical adoption of precision oncology workflows across a healthcare network","volume":"27","author":"Dias-Santagata","year":"2022","journal-title":"Oncologist"},{"issue":"13","key":"10.1016\/j.addr.2026.115921_bb1150","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.3390\/cancers16132484","article-title":"Devices and methods for dosimetry of personalized photodynamic therapy of Tumors: A review on recent trends","volume":"16","author":"Alekseeva","year":"2024","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.addr.2026.115921_bb1155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.110027","article-title":"Specialised oncology training for effective multidisciplinary cancer care","volume":"51","author":"Kaul","year":"2025","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.addr.2026.115921_bb1160","series-title":"Epigenetic Regulation in Overcoming Chemoresistance","first-page":"85","article-title":"Chapter 7 - the combination strategy with epigenetic therapy, chemotherapy, and immunotherapy","volume":"15","author":"Wen","year":"2021"},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb1165","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13148-025-01856-6","article-title":"Epigenetic regulators combined with tumour immunotherapy: current status and perspectives","volume":"17","author":"Zhang","year":"2025","journal-title":"Clin. Epigenetics"},{"issue":"3","key":"10.1016\/j.addr.2026.115921_bb1170","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/ijms21030998","article-title":"Chemical and light inducible epigenome editing","volume":"21","author":"Zhao","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb1175","doi-asserted-by":"crossref","first-page":"10310","DOI":"10.1038\/s41467-024-54781-2","article-title":"A sensitive red\/far-red photoswitch for controllable gene therapy in mouse models of metabolic diseases","volume":"15","author":"Qiao","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb1180","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41467-021-20913-1","article-title":"A synthetic BRET-based optogenetic device for pulsatile transgene expression enabling glucose homeostasis in mice","volume":"12","author":"Li","year":"2021","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.addr.2026.115921_bb1185","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41592-021-01238-9","article-title":"Chronically implantable LED arrays for behavioral optogenetics in primates","volume":"18","author":"Rajalingham","year":"2021","journal-title":"Nat. Methods"},{"key":"10.1016\/j.addr.2026.115921_bb1190","doi-asserted-by":"crossref","DOI":"10.1016\/j.cobme.2023.100477","article-title":"Advancing CRISPR\/Cas gene editing with machine learning","volume":"28","author":"Fong","year":"2023","journal-title":"Current Opinion in Biomedical Engineering"},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb1195","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/s41467-025-67848-5","article-title":"Closed-loop optogenetic control of cell biology enables outcome-driven microscopy","volume":"17","author":"Passmore","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115921_bb1200","doi-asserted-by":"crossref","unstructured":"Waldo, J. J., Halmai, J. A. N. M., & Fink, K. D. (2024). Epigenetic editing for autosomal dominant neurological disorders [review]. Front. Genome Ed., Volume 6\u20132024. Doi: https:\/\/doi.org\/10.3389\/fgeed.2024.1304110.","DOI":"10.3389\/fgeed.2024.1304110"},{"issue":"21","key":"10.1016\/j.addr.2026.115921_bb1205","doi-asserted-by":"crossref","first-page":"11658","DOI":"10.3390\/ijms252111658","article-title":"Epigenetic explorations of neurological disorders, the identification methods, and therapeutic avenues","volume":"25","author":"Firdaus","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2026.115921_bb1210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177853","article-title":"Epigenetic reprogramming as a therapeutic strategy for neurodegenerative diseases: A complex and novel approach","volume":"1002","author":"Alkhammash","year":"2025","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.addr.2026.115921_bb1215","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41431-024-01555-5","article-title":"What is the power of a genomic multidisciplinary team approach? A systematic review of implementation and sustainability","volume":"32","author":"Ma","year":"2024","journal-title":"Eur. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.addr.2026.115921_bb1220","article-title":"Institutional readiness for novel therapeutics: A framework for multidisciplinary integration","volume":"146","author":"Ames","year":"2025","journal-title":"Mol. Genet. Metab."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26001559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26001559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:49:46Z","timestamp":1783774186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X26001559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":244,"alternative-id":["S0169409X26001559"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2026.115921","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Light-controlled CRISPR\u2013dCas9 epigenome editing: advanced drug-delivery strategies and oncology applications","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2026.115921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115921"}}